Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases

por Giembycz, Mark A., Newton, Robert
Publicado 2015

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

por Giembycz, Mark A, Field, Stephen K
Publicado 2010

A bronchoprotective role for Rgs2 in a murine model of lipopolysaccharide-induced airways inflammation

por George, Tresa, Chakraborty, Mainak, Giembycz, Mark A., Newton, Robert
Publicado 2018

Cytokine-Induced Loss of Glucocorticoid Function: Effect of Kinase Inhibitors, Long-Acting β2-Adrenoceptor Agonist and Glucocorticoid Receptor Ligands

por Rider, Christopher F., Shah, Suharsh, Miller-Larsson, Anna, Giembycz, Mark A., Newton, Robert
Publicado 2015

Protective Roles for RGS2 in a Mouse Model of House Dust Mite-Induced Airway Inflammation

por George, Tresa, Bell, Matthew, Chakraborty, Mainak, Siderovski, David P., Giembycz, Mark A., Newton, Robert
Publicado 2017

Glucocorticoid Repression of Inflammatory Gene Expression Shows Differential Responsiveness by Transactivation- and Transrepression-Dependent Mechanisms

por King, Elizabeth M., Chivers, Joanna E., Rider, Christopher F., Minnich, Anne, Giembycz, Mark A., Newton, Robert
Publicado 2013

Tumour Necrosis Factor-α Regulates Human Eosinophil Apoptosis via Ligation of TNF-Receptor 1 and Balance between NF-κB and AP-1

por Kankaanranta, Hannu, Ilmarinen, Pinja, Zhang, Xianzhi, Adcock, Ian M., Lahti, Aleksi, Barnes, Peter J., Giembycz, Mark A., Lindsay, Mark A., Moilanen, Eeva
Publicado 2014